Total Payments
$3,793
2024 Payments
$277.92
Companies
19
Transactions
38
Medicare Patients
1,225
Medicare Billing
$207,930
Payment Breakdown by Category
Food & Beverage$3,658 (96.4%)
Consulting$133.75 (3.5%)
Education$1.25 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,658 | 36 | 96.4% |
| Consulting Fee | $133.75 | 1 | 3.5% |
| Education | $1.25 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Neurocrine Biosciences, Inc. | $523.86 | 4 | $0 (2024) |
| ABBVIE INC. | $512.87 | 5 | $0 (2023) |
| Amgen Inc. | $362.41 | 3 | $0 (2021) |
| Biogen, Inc. | $266.27 | 3 | $0 (2020) |
| SK Life Science, Inc. | $248.60 | 3 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $248.40 | 2 | $0 (2022) |
| Eisai Inc. | $240.80 | 2 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $210.77 | 2 | $0 (2018) |
| ACADIA Pharmaceuticals Inc | $198.48 | 3 | $0 (2022) |
| Octapharma USA, Inc. | $133.75 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $277.92 | 3 | Neurocrine Biosciences, Inc. ($133.22) |
| 2023 | $339.54 | 3 | Neurocrine Biosciences, Inc. ($132.32) |
| 2022 | $923.00 | 10 | Neurocrine Biosciences, Inc. ($140.00) |
| 2021 | $244.38 | 2 | AstraZeneca Pharmaceuticals LP ($123.52) |
| 2020 | $170.40 | 3 | Amgen Inc. ($120.77) |
| 2019 | $99.34 | 1 | EMD Serono, Inc. ($99.34) |
| 2018 | $834.33 | 7 | Biogen, Inc. ($241.37) |
| 2017 | $903.91 | 9 | AbbVie, Inc. ($331.20) |
All Payment Transactions
38 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/16/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | Cash or cash equivalent | $120.35 | General |
| Category: Neurology | ||||||
| 08/21/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $133.22 | General |
| Category: Neuropsychiatry | ||||||
| 02/12/2024 | Merck Sharp & Dohme LLC | BRIDION (Drug) | Food and Beverage | In-kind items and services | $24.35 | General |
| Category: NEUROSCIENCE | ||||||
| 09/21/2023 | SK Life Science, Inc. | XCOPRI (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Neurology | ||||||
| 05/10/2023 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $132.32 | General |
| Category: Neuropsychiatry | ||||||
| 02/23/2023 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $82.22 | General |
| Category: NEUROSCIENCE | ||||||
| 12/08/2022 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $123.28 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/15/2022 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $124.24 | General |
| Category: NEUROSCIENCE | ||||||
| 11/03/2022 | SK Life Science, Inc. | XCOPRI (Drug) | Food and Beverage | In-kind items and services | $122.35 | General |
| Category: Neurology | ||||||
| 10/11/2022 | Genentech, Inc. | — | Food and Beverage | In-kind items and services | $78.81 | General |
| 08/24/2022 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $99.45 | General |
| Category: NEUROSCIENCE | ||||||
| 07/19/2022 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | Cash or cash equivalent | $140.00 | General |
| Category: Neuropsychiatry | ||||||
| 07/12/2022 | SK Life Science, Inc. | XCOPRI (Drug) | Education | In-kind items and services | $1.25 | General |
| Category: Neurology | ||||||
| 04/20/2022 | AstraZeneca Pharmaceuticals LP | ANDEXXA (Biological) | Food and Beverage | In-kind items and services | $124.88 | General |
| Category: Rare Disease | ||||||
| 03/17/2022 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $77.49 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 02/10/2022 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $31.25 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 11/04/2021 | Amgen Inc. | Aimovig (Biological) | Food and Beverage | In-kind items and services | $120.86 | General |
| Category: Neuroscience | ||||||
| 05/19/2021 | AstraZeneca Pharmaceuticals LP | BRILINTA (Drug) | Food and Beverage | In-kind items and services | $123.52 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/15/2020 | Allergan, Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $24.73 | General |
| Category: NEUROSCIENCE | ||||||
| 07/20/2020 | Biogen, Inc. | VUMERITY (Drug) | Food and Beverage | In-kind items and services | $24.90 | General |
| Category: NEUROLOGY | ||||||
| 03/05/2020 | Amgen Inc. | Aimovig (Biological) | Food and Beverage | In-kind items and services | $120.77 | General |
| Category: Neuroscience | ||||||
| 03/28/2019 | EMD Serono, Inc. | Rebif (Biological) | Food and Beverage | In-kind items and services | $99.34 | General |
| Category: Neurology | ||||||
| 08/23/2018 | Biogen, Inc. | TYSABRI (Biological) | Food and Beverage | Cash or cash equivalent | $117.13 | General |
| Category: NEUROLOGY | ||||||
| 07/31/2018 | Merz North America, Inc. | XEOMIN (Biological) | Food and Beverage | Cash or cash equivalent | $124.18 | General |
| Category: MUSCULOSKELETAL | ||||||
| 06/20/2018 | Biogen, Inc. | TECFIDERA (Drug) | Food and Beverage | Cash or cash equivalent | $124.24 | General |
| Category: NEUROLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 325 | 630 | $115,150 | $52,141 |
| 2022 | 8 | 358 | 680 | $128,630 | $62,084 |
| 2021 | 8 | 269 | 504 | $87,580 | $48,960 |
| 2020 | 8 | 273 | 453 | $69,295 | $44,746 |
Total Patients
1,225
Total Services
2,267
Medicare Billing
$207,930
Procedure Codes
32
All Medicare Procedures & Services
32 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 57 | 290 | $40,600 | $19,224 | 47.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 65 | 65 | $22,750 | $9,445 | 41.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 36 | 36 | $13,500 | $6,430 | 47.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 40 | 41 | $10,250 | $6,327 | 61.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 41 | 44 | $8,800 | $4,750 | 54.0% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2023 | 16 | 32 | $5,600 | $2,814 | 50.2% |
| G0316 | Prolonged hospital inpatient or observation care evaluation and management service(s) beyond the total time for the primary service (when the primary service has been selected using time on the date of the primary service); each additional 15 minutes by th | Facility | 2023 | 54 | 102 | $11,250 | $2,609 | 23.2% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 16 | 20 | $2,400 | $543.00 | 22.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 63 | 349 | $48,860 | $21,022 | 43.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 67 | 69 | $24,150 | $11,560 | 47.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 48 | 48 | $18,000 | $9,277 | 51.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 55 | 57 | $14,250 | $8,789 | 61.7% |
| 99356 | Extended inpatient or observation hospital service, first hour | Facility | 2022 | 61 | 62 | $9,920 | $4,755 | 47.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 32 | 33 | $6,600 | $3,510 | 53.2% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2022 | 12 | 22 | $3,850 | $2,038 | 52.9% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2022 | 20 | 40 | $3,000 | $1,133 | 37.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 41 | 230 | $26,250 | $14,138 | 53.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 43 | 49 | $15,650 | $8,395 | 53.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 47 | 52 | $11,970 | $8,273 | 69.1% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 40 | 40 | $13,500 | $7,536 | 55.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 31 | 40 | $7,120 | $4,157 | 58.4% |
| 99356 | Prolonged inpatient or observation hospital service, first hour | Facility | 2021 | 39 | 39 | $6,240 | $3,065 | 49.1% |
| 95886 | Needle measurement and recording of electrical activity of muscles of arm or leg complete study | Office | 2021 | 15 | 28 | $4,900 | $2,647 | 54.0% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2021 | 13 | 26 | $1,950 | $747.37 | 38.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 33 | 194 | $17,460 | $12,084 | 69.2% |
About Dr. Duke Phan, MD
Dr. Duke Phan, MD is a Neurology healthcare provider based in Fountain Valley, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/06/2007. The National Provider Identifier (NPI) number assigned to this provider is 1437352630.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Duke Phan, MD has received a total of $3,793 in payments from pharmaceutical and medical device companies, with $277.92 received in 2024. These payments were reported across 38 transactions from 19 companies. The most common payment nature is "Food and Beverage" ($3,658).
As a Medicare-enrolled provider, Phan has provided services to 1,225 Medicare beneficiaries, totaling 2,267 services with total Medicare billing of $207,930. Data is available for 4 years (2020–2023), covering 32 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Fountain Valley, CA
- Active Since 06/06/2007
- Last Updated 03/07/2023
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1437352630
Products in Payments
- INGREZZA (Drug) $523.86
- Duopa (Drug) $331.20
- XCOPRI (Drug) $248.60
- Aimovig (Biological) $241.63
- AUSTEDO (Drug) $210.77
- NUPLAZID (Drug) $198.48
- QULIPTA (Drug) $181.67
- OCTAGAM (Biological) $133.75
- ANDEXXA (Biological) $124.88
- KESIMPTA (Drug) $124.24
- TECFIDERA (Drug) $124.24
- XEOMIN (Biological) $124.18
- BRILINTA (Drug) $123.52
- DUPIXENT (Biological) $123.28
- GOCOVRI (Drug) $121.04
- Fycompa (Drug) $120.45
- Leqembi (Drug) $120.35
- TYSABRI (Biological) $117.13
- ACTIVA (Device) $106.19
- Rebif (Biological) $99.34
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Fountain Valley
Dr. Daniel Truong, M.d, M.D
Neurology — Payments: $198,412
Neurology $198,412
Kong Truong, M.d, M.D
Neurology — Payments: $30,261
Neurology $30,261
Dr. Nancy Vu, M.d, M.D
Neurology — Payments: $28,653
Neurology $28,653
Deepmala Nandanwar, M.d, M.D
Neurology — Payments: $24,211
Neurology $24,211
Frank Xing
Neurology — Payments: $19,618
Neurology $19,618
Dr. Mehrdad Mahdad, M.d, M.D
Neurology — Payments: $12,845
Neurology $12,845